Oncolytics Biotech Inc. is a biotech company that is focused on developing a new treatment for cancer called pelareorep. The treatment is delivered intravenously and is designed to target cancer through a mechanism of action that involves selective tumor lysis and activation of the innate and adaptive immune systems. This creates an inflamed phenotype, which the company hopes will be effective in treating a range of solid tumors and hematological malignancies. The treatment is described as safe and well-tolerated, and the company is working to bring it to market as soon as possible.
Oncolytics Biotech Inc.'s ticker is ONC
The company's shares trade on the LSE stock exchange
They are based in Nottingham, England
There are 51-200 employees working at Oncolytics Biotech Inc.
It is https://www.oncolyticsbiotech.com/
Oncolytics Biotech Inc. is in the Healthcare sector
Oncolytics Biotech Inc. is in the Biotechnology industry
The following five companies are Oncolytics Biotech Inc.'s industry peers: